GlassScriptPhysician profile
Lacey Vasilakis
NPI 1083056915
$16,894.94
in general payments reported to CMS, 2019-2025
66 companies · $3,168 in 2025
The $3,168 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,362 · 2022: $2,282 · 2023: $2,812 · 2024: $3,271 · 2025: $3,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,094 · Long Term Medical Supply Or Device Loan: $665 · Education: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,094.33 |
| Long Term Medical Supply Or Device Loan | $665.16 |
| Education | $490.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $3,720.12 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $1,734.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $932.63 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $804.49 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $629.03 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $598.70 | 2021-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Celgene Corporation | $593.76 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $535.07 | 2021-2025 | Vyloy, Xtandi, Padcev |
| Amgen INC. | $514.37 | 2021-2025 | Kyprolis, Blincyto, Kyprolis |
| Eli Lilly and Company | $500.00 | 2021 | |
| Pfizer INC. | $468.23 | 2021-2025 | |
| Janssen Biotech, INC. | $396.15 | 2021-2025 | Darzalex, Tecvayli, Imbruvica |
| Eisai INC. | $332.81 | 2021-2025 | |
| Genzyme Corporation | $326.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $274.16 | 2021-2025 | Opdivo |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $273.42 | 2021-2025 | Tivdak, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $270.00 | 2022-2025 | |
| Beigene USA, INC. | $220.07 | 2021-2024 | Brukinsa |
| Incyte Corporation | $215.00 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Sobi, INC | $206.41 | 2022-2025 | |
| Genentech USA, INC. | $196.65 | 2022-2025 | Polivy, Columvi, Lunsumio |
| Sanofi-Aventis U.S. LLC | $192.98 | 2023-2025 | |
| Seagen INC. | $180.38 | 2022-2023 | Adcetris, Tukysa |
| Taiho Oncology, INC. | $177.30 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.29 | 2021-2025 | Gilotrif |
| Puma Biotechnology, INC. | $161.18 | 2021-2025 | |
| Abbvie INC. | $150.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $148.32 | 2021-2025 | Libtayo |
| Stemline Therapeutics INC. | $139.02 | 2023-2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $133.63 | 2024-2025 | Clonoseq |
| Mirati Therapeutics, INC. | $126.71 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $119.83 | 2021-2025 | |
| Exelixis INC. | $118.38 | 2021-2024 | Cabometyx |
| Emd Serono, INC. | $112.88 | 2021-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $111.14 | 2021-2025 | Somatuline Depot, Onivyde, Tazverik |
| Servier Pharmaceuticals LLC | $107.74 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $86.53 | 2021-2025 | Fotivda |
| Blueprint Medicines Corporation | $83.87 | 2022-2023 | Ayvakit |
| Glaxosmithkline, LLC. | $68.20 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Pharmacosmos Therapeutics INC. | $62.98 | 2021 | |
| Array Biopharma INC | $61.57 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $52.02 | 2023-2025 | Trodelvy |
| Progenics Pharmaceuticals, INC. | $48.11 | 2022-2023 | Pylarify |
| Tempus Ai, INC | $44.23 | 2025 | Xt Cdx |
| Geron Corporation | $41.48 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $41.05 | 2025 | Brukinsa |
| Global Blood Therapeutics, INC. | $37.84 | 2021-2022 | |
| Springworks Therapeutics, INC. | $37.34 | 2024-2025 | Ogsiveo |
| Tersera Therapeutics LLC | $31.81 | 2025 | Xermelo |
| Karyopharm Therapeutics INC. | $31.44 | 2021-2023 | Xpovio |
| Catalyst Pharmaceuticals, INC. | $24.21 | 2024 | |
| Legend Biotech USA INC. | $24.12 | 2025 | Carvykti |
| Syndax Pharmaceuticals, INC. | $23.07 | 2025 | |
| Acrotech Biopharma INC. | $22.35 | 2025 | Beleodaq |
| Acceleron Pharma, INC. | $20.32 | 2021 | |
| Recordati_rare_diseases_inc. | $19.89 | 2025 | Sylvant |
| Dova Pharmaceuticals | $19.59 | 2021 | |
| Rigel Pharmaceuticals, INC. | $16.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.90 | 2022 | |
| Agios Pharmaceuticals, INC. | $15.88 | 2025 | Pyrukynd |
| Chiesi USA, INC. | $14.74 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.39 | 2021 | |
| Janssen Scientific Affairs, LLC | $14.38 | 2023 | Darzalex, Tecvayli |
| Coherus Oncology, INC. | $12.86 | 2022 | |
| Emmaus Medical, INC. | $10.55 | 2023 | Endari |
| Pharmaand Gmbh | $9.35 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Vasilakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.